Lisa Rahangdale, MD, MPH - Division of Women's Primary Healthcare
This is a prospective randomized-controlled trial of treatment with intravaginal 5% 5-Fluorouracil (5-FU) versus placebo in women with CIN 2. The purpose of this study is to assess clearance of dysplasia and/or HPV and to evaluate the acceptability of 5-FU for the treatment of cervical dysplasia. Women aged 18- 30 with biopsy-confirmed CIN 2 presenting for treatment at the UNC Hospital facilities will be randomized into a control group (placebo) and treatment group (5-FU group). Acceptability and gynecologic symptoms will be monitored by self-report, survey and colposcopic evaluation between 8-16 weeks. Evaluation of cervical disease will occur at 6 months and 12 months by cytology, HPV testing, and colposcopy.